Darexaban

Summary

Darexaban (CHEMBL1922235) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including venous thromboembolism and atrial fibrillation.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 25
• Chemistry: 474.6 Da · C27H30N4O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1922235
Name	Darexaban
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9912771
Molecular formula	C27H30N4O4
Molecular weight	474.6
InChIKey	IJNIQYINMSGIPS-UHFFFAOYSA-N

SMILES: CN1CCCN(CC1)C2=CC=C(C=C2)C(=O)NC3=C(C=CC=C3O)NC(=O)C4=CC=C(C=C4)OC

IUPAC name: N-[2-hydroxy-6-[(4-methoxybenzoyl)amino]phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide

Also known as: Darexaban, Tanexaban, YM-150, YM150, DAREXABAN

Parent form; salt/anhydrous children: CHEMBL1922345, CHEMBL3527359

Patent coverage: 248 distinct patent families (710 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Plasma kallikrein, Coagulation factor X.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
F10	7.51	Ki	31	nM	CHEMBL_ACT_7951467
F10	7.26	IC50	54.6	nM	CHEMBL_ACT_7951488

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
venous thromboembolism	3	MONDO:0005399	EFO:0004286
atrial fibrillation	2	MONDO:0004981	EFO:0000275
acute coronary syndrome	2	MONDO:0005542	EFO:0005672

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 25.

Phase distribution

Phase	Trials
PHASE1	12
PHASE2	6
PHASE3	4
PHASE2/PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00902928	PHASE2/PHASE3	COMPLETED	A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery
NCT00913120	PHASE2/PHASE3	COMPLETED	Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery
NCT00917254	PHASE2/PHASE3	COMPLETED	Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
NCT00937820	PHASE3	COMPLETED	Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism
NCT00937911	PHASE3	COMPLETED	Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities
NCT00942435	PHASE3	COMPLETED	A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
NCT01028950	PHASE3	COMPLETED	YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness
NCT00353678	PHASE2	COMPLETED	Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)
NCT00408239	PHASE2	COMPLETED	Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement
NCT00448214	PHASE2	COMPLETED	Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
NCT00595426	PHASE2	COMPLETED	A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery
NCT00938730	PHASE2	COMPLETED	A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation
NCT00994292	PHASE2	COMPLETED	Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes
NCT01118559	PHASE1	COMPLETED	A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150
NCT01125657	PHASE1	COMPLETED	A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-B
NCT01125670	PHASE1	COMPLETED	A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 Tablet
NCT01405989	PHASE1	COMPLETED	To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban)
NCT01406002	PHASE1	COMPLETED	To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)
NCT01409603	PHASE1	COMPLETED	To Evaluate Whether Naproxen and Darexaban (YM150) Interact in Their Effects
NCT01409616	PHASE1	COMPLETED	To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects
NCT01424332	PHASE1	COMPLETED	To Evaluate Whether Acetyl Salicylic Acid (Aspirin) and Darexaban (YM150) Interact in Their Effects
NCT01514812	PHASE1	COMPLETED	A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy Subjects
NCT01514825	PHASE1	COMPLETED	A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects
NCT01655056	PHASE1	COMPLETED	A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body
NCT01657981	PHASE1	COMPLETED	A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).